The German biotechnology company BioNTech announced today (May 10) that it will establish a regional headquarters in Singapore.
The new headquarters in Singapore will also have a fully integrated mRNA production facility and will be supported by the Economic Development Board (EDB) in Singapore.
This move is part of the country's strategy to grow the biopharmaceutical industry here, and EBD Chairman Beh Swan Gin said the investment will enable Singapore to "develop skills in an important new therapy modality".
BioNTech Co-Founder and CEO Ugur Sahin also noted that Singapore has "an excellent business climate" and the opening of the regional headquarters is a strategic move for the company to expand its global presence. "
BioNTech's Singapore office is scheduled to open in 2021. Then the construction of the production facility should begin.
According to the company, the facility could be operational as early as 2023 and create up to 80 jobs in Singapore. However, no information has been released regarding the amount the company has invested in Singapore.
BioNTech said in a press release that the new mRNA manufacturing facility "will leverage state-of-the-art manufacturing and digital infrastructure" and "will be equipped to manufacture a variety of novel vaccines and messenger RNA (mRNA) therapeutics for infectious diseases and cancer."
The company had partnered with Pfizer to develop a Covid-19 vaccine using mRNA technology.
The Health Sciences Authority (HSA) has assessed that Pfizer-BioNTech and Moderna COVID-19 vaccines – the two vaccines currently available in Singapore – meet safety and efficacy standards.
Last month, the Ministry of Health announced that people under the age of 45 will soon be able to book their vaccination spots. This means that the Covid-19 vaccination will be made available to all Singaporeans over the age of 16.
Selected image source: World Pharma Today